Vanda Pharmaceuticals Stock Performance
| VNDA Stock | USD 4.98 0.06 1.22% |
Vanda Pharmaceuticals has a performance score of 3 on a scale of 0 to 100. The entity has a beta of 0.12, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Vanda Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Vanda Pharmaceuticals is expected to be smaller as well. Vanda Pharmaceuticals right now has a risk of 2.55%. Please validate Vanda Pharmaceuticals expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if Vanda Pharmaceuticals will be following its existing price patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vanda Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating fundamental indicators, Vanda Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 136.3 M |
Vanda |
Vanda Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 473.00 in Vanda Pharmaceuticals on December 17, 2024 and sell it today you would earn a total of 27.00 from holding Vanda Pharmaceuticals or generate 5.71% return on investment over 90 days. Vanda Pharmaceuticals is currently generating 0.1229% in daily expected returns and assumes 2.5499% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Vanda, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vanda Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vanda Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vanda Pharmaceuticals, and traders can use it to determine the average amount a Vanda Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0482
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | VNDA | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.55 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Vanda Pharmaceuticals is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vanda Pharmaceuticals by adding it to a well-diversified portfolio.
Vanda Pharmaceuticals Fundamentals Growth
Vanda Stock prices reflect investors' perceptions of the future prospects and financial health of Vanda Pharmaceuticals, and Vanda Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vanda Stock performance.
| Return On Equity | -0.0302 | ||||
| Return On Asset | -0.0364 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | (71.29 M) | ||||
| Shares Outstanding | 58.31 M | ||||
| Price To Earning | 24.83 X | ||||
| Price To Book | 0.54 X | ||||
| Price To Sales | 1.46 X | ||||
| Revenue | 198.77 M | ||||
| EBITDA | (40.66 M) | ||||
| Cash And Equivalents | 440.86 M | ||||
| Cash Per Share | 7.79 X | ||||
| Total Debt | 12.36 M | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | 9.28 X | ||||
| Cash Flow From Operations | (15.76 M) | ||||
| Earnings Per Share | (0.19) X | ||||
| Total Asset | 656.2 M | ||||
| Retained Earnings | (174.29 M) | ||||
| Current Asset | 166.55 M | ||||
| Current Liabilities | 51.32 M | ||||
About Vanda Pharmaceuticals Performance
By analyzing Vanda Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Vanda Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Vanda Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vanda Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. Vanda Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 278 people.Things to note about Vanda Pharmaceuticals performance evaluation
Checking the ongoing alerts about Vanda Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vanda Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 198.77 M. Net Loss for the year was (18.9 M) with profit before overhead, payroll, taxes, and interest of 230.1 M. | |
| Vanda Pharmaceuticals currently holds about 440.86 M in cash with (15.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 77.0% of the company outstanding shares are owned by institutional investors |
- Analyzing Vanda Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vanda Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Vanda Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vanda Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vanda Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vanda Pharmaceuticals' stock. These opinions can provide insight into Vanda Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Vanda Stock analysis
When running Vanda Pharmaceuticals' price analysis, check to measure Vanda Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vanda Pharmaceuticals is operating at the current time. Most of Vanda Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vanda Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vanda Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vanda Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |